No alternative for Phosphagenics
Wednesday, 24 September, 2008
Phosphagenics (ASX: POH) will cease trading on the Alternative Investment Market (AIM) of the British stock exchange.
According to Phosphagenics, monthly turnover of the company's AIM shares has decreased since listing four years ago, whereas turnover on the company's ASX shares have increased.
The Melbourne company has begun a Phase I clinical trial of its patented delivery system, TPM, for the topical delivery of the pain relief drug lidocaine.
The trial is being conducted at the Centre for Pharmaceutical Research at the University of South Australia.
The company expects early results in the first quarter of 2009.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
